We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

1 hedge funds and large institutions have $16 invested in Avadel Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

50% less funds holding

Funds holding: 2 → 1 (-1)

96% less capital invested

Capital invested by funds: $442 → $16 (-$426)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
-$426

AVDL Hedge Fund Activity: Q2 2026 in Review

1 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2026, worth a combined $16 — down 96% from $442 a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of AVDL and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was IFP Advisors, exiting entirely with an estimated $426 sold.

  • 1 institutional investor held Avadel Pharmaceuticals (AVDL) as of Q2 2026, down from 2 in Q1 2026.
  • Funds reported $16 of Avadel Pharmaceuticals stock for Q2 2026, down 96% quarter-over-quarter.
  • 0 funds opened new Avadel Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of -1 holder.
  • The largest Avadel Pharmaceuticals seller in Q2 2026 was IFP Advisors, an estimated $426 sold.

Based on aggregated 13F filings for Q2 2026.